Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Neuronetics, Inc.STIM · Entity 6248 | 10% owner | August 13, 2026 | August 17, 2026 |
| Starling Oncology, Inc.STLN · Entity 5327 | 10% owner | August 13, 2026 | August 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Neuronetics, Inc.
Report date August 13, 2026 · Filed August 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,602,988 |
Reported balance
After 2026-08-14 transaction · row 1
1 source rowRow 1 · 2026-08-14 · Purchase · Acquired 14,000 · Balance 10,602,988 F1: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $3.13 tgo $3.17 rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. |
| Call Option (STIM 19FEB27 $5C)SEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2027-02-19 | Direct | 0 |
Reported balance
After 2026-08-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-13 · Sale · Disposed 100 · Balance 0 F2: The sale of these call options is a matchable transaction subject to Section 16(b) of the Securities Exchange Act of 1934. The reporting person has calculated a short-swing profit in connection with such matchable transactions, which the reporting person intends to disgorge to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $3.13 tgo $3.17 rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased.
F2: The sale of these call options is a matchable transaction subject to Section 16(b) of the Securities Exchange Act of 1934. The reporting person has calculated a short-swing profit in connection with such matchable transactions, which the reporting person intends to disgorge to the Issuer.
Starling Oncology, Inc.
Report date August 13, 2026 · Filed August 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,660,858 |
Reported balance
After 2026-08-14 transaction · row 1
1 source rowRow 1 · 2026-08-14 · Purchase · Acquired 12,000 · Balance 10,660,858 |
| Call Option (STLN 19FEB27 $9C)SEC Table II · derivative / convertible security · Conversion / exercise price $9.00 · Expires 2027-02-19 | Direct | 0 |
Reported balance
After 2026-08-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-13 · Sale · Disposed 100 · Balance 0 F1: The sale of these call options is a matchable transaction subject to Section 16(b) of the Securities Exchange Act of 1934. The reporting person has calculated a short-swing profit in connection with such matchable transactions, which the reporting person intends to disgorge to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale of these call options is a matchable transaction subject to Section 16(b) of the Securities Exchange Act of 1934. The reporting person has calculated a short-swing profit in connection with such matchable transactions, which the reporting person intends to disgorge to the Issuer.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Airsculpt Technologies, Inc.
Report date April 17, 2026 · Filed April 20, 2026
Section 16 reporting ended · disclosed 2026-04-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,053,761 |
Reported balance
After 2026-04-17 transaction · row 1
1 source rowRow 1 · 2026-04-17 · Purchase · Acquired 40,000 · Balance 7,053,761 F1: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $2.52 to $2.56, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. |
| Call Option (AIRS 17APR26 $4C)SEC Table II · derivative / convertible security · Conversion / exercise price $4.00 · Expires 2026-04-17 | Direct | 0 |
Reported balance
After 2026-04-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-17 · Other · Disposed 2,004 · Balance 0 F2: These call options expired unexercised on April 17, 2026, as the market price of the underlying common stock was below the exercise price of the options at the time of expiration. No consideration was received by the Reporting Person in connection with this expiration. |
| Call Option (AIRS 17APR26 $5C)SEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2026-04-17 | Direct | 0 |
Reported balance
After 2026-04-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-17 · Other · Disposed 2,000 · Balance 0 F2: These call options expired unexercised on April 17, 2026, as the market price of the underlying common stock was below the exercise price of the options at the time of expiration. No consideration was received by the Reporting Person in connection with this expiration. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $2.52 to $2.56, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased.
F2: These call options expired unexercised on April 17, 2026, as the market price of the underlying common stock was below the exercise price of the options at the time of expiration. No consideration was received by the Reporting Person in connection with this expiration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2026 Filed Mar 4, 2026 23:58 UTC | Airsculpt Technologies, Inc. AIRS · Entity 6404 | PurchaseCommon Stock | 80,000 | $1.71 | $136,800.00 |
DisclosureSEC source: 0000921895-26-000613 · form414528003_03042026.xml · nonDerivative · entry 1 Chernett Jorey · CIK 0002042077 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,322,611 F1 · price: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $1.67 to $1.77, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.